bluuebunny/crossref_metadata_2025_split huggingface dataset:
Executive function, limbic circuit dynamics and repetitive and restricted behaviors in children with autism spectrum disorder
Authors: Zheng Xiangyu , Wang Xinyue , Song Ruochen , Tian Junbin , Yang Li 
Published: January 2025

ObjectiveRepetitive and restricted behaviors (RRBs) are a core symptom of autism spectrum disorder (ASD), but effective treatment approaches are still lacking. Executive function (EF) has been identified as a promising target, as research increasingly shows a link between EF deficits and the occurrence of RRBs. However, the neural mechanisms that connect the two remain unclear. Since the orbitofrontal cortex (OFC) plays a role in both EF and RRBs, its functional connectivity dynamics could offer valuable insights into this relationship.MethodsThis study analyzed data from the Autism Brain Imaging Data Exchange (ABIDE) II database to explore brain function in 93 boys with ASD and 110 typically developing (TD) boys. Time-varying functional connectivity was analyzed between eight OFC subregions and other brain areas. By employing linear regression, the study assessed how atypical connectivity dynamics and EF influence RRBs. Additionally, mediation analysis with bootstrapping was used to determine how EF mediates the relationship between atypical connectivity and RRBs.ResultsWe found significant differences in the variance of FC between ASD and TD groups, specifically in the OFC subregion in L-prefrontal and the left amygdala (t = 5.00, FDR q &lt; 0.01). Regression analyses revealed that increased variance of this FC and EF significantly impacted RRBs, with inhibition, emotional control, and monitor showing strong associations (standardized β = 0.60 to 0.62, p &lt; 0.01), which also had significant indirect effects on the relationship between the above dynamic FC and RRBs, which accounted for 59% of the total effect.ConclusionThis study highlights the critical role of EFs as a key mechanism in addressing RRBs in ASD. Specifically, it points out that EFs mediate the influence of atypical time-varying interactions within the OFC-amygdala circuit on RRBs.
Evaluation of Bacillus coagulans LMG S-31876 for immunomodulation and stress: a double-blind, placebo-controlled clinical trial
Authors: Kallur Ranjith Kumar , Madapati Sreenadh , Banerjee Mayuri , Mathur Ankita , Bhattacharya Sourish 
Published: January 2025

ObjectiveThe study aimed to analyze the safety and effectiveness of the ProBC Plus (Bacillus coagulans LMG S-31876) supplement across various health parameters, including stress levels, immunoglobulin levels, biochemical parameters, and vital signs.MethodsA randomized, double-blind, placebo-controlled clinical trial study was conducted involving 50 subjects diagnosed with ailments related to immune system dysfunction and stress related disorders. Patients were treated with ProBC Plus (2 billion colony-forming units [CFU]) along with a placebo capsule administered once daily for a period of 8 weeks.ResultsThe effects of ProBC Plus exhibited a positive response on stress relief, lipid parameters, immune status, and vital signs, which is further statistically significant (p value &lt;0.05, 5% marginal error at 95% CI).ConclusionThe study on ProBC Plus showed positive results. Over the course of 8 weeks, an improvement in the immune status was observed, as indicated by the immune status questionnaire. Enzymatic markers exhibited a significant decline in predicting a positive response toward treatment. In terms of lipid profile, ProBC Plus helps to maintain the value within the normal range, thereby predicting its potential as cardiovascular support. The vital signs remained within the normal range throughout the study. Therefore, ProBC Plus is considered safe for consumption and contributes to the overall well-being of individuals.Clinical trial registrationhttps://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=77914&amp;EncHid=24313.96864&amp;userName=CTRI/2023/01/048720, CTRI/2023/01/048720.
Global burden of chronic kidney disease due to dietary factors
Authors: Yin Lingtao , Kuai Mengni , Liu Zhuo , Zou Binbin , Wu Ping 
Published: January 2025

BackgroundWe aimed to assess the global impact of chronic kidney disease (CKD) attributable to dietary risk factors.MethodsThe research utilized data from the Global Burden of Disease Study 2021 to evaluate age-standardized mortality rates (ASMR), disability-adjusted life years (DALYs), and estimated annual percentage changes (EAPCs) linked to CKD resulting from dietary risk factors.ResultsFrom 1990 to 2021, both the ASMR and age-standardized DALY rate (ASDR) for CKD attributable to dietary risk factors exhibited an overall increasing trend globally. The mortality EAPC was 0.65, while the EAPC for DALYs stood at 0.39. Among dietary risk factors examined, a diet high in sugar-sweetened beverages was associated with the most substantial increase in CKD burden. Notably, Central sub-Saharan Africa bore the highest burden of CKD due to dietary risk factors, with an ASMR of 10.24 and an ASDR of 229.23. The increases in ASMR and ASDR were more pronounced in high-income regions, particularly in Latin America and the Caribbean, where the EAPC values for ASMR were 1.45 and 1.05, respectively, and for ASDR were 1.08 and 0.96. Furthermore, the burden of CKD was notably higher among middle-aged and elderly individuals, especially men aged 65 and above.ConclusionThe global disease burden attributed to dietary risk factors for CKD is increasing. A diet high in sugar-sweetened beverages exerted the most significant impact on CKD. There is a high incidence in Central sub-Saharan Africa, as well as in high-income regions and Latin America and the Caribbean.
The burden of chronic kidney disease attributable to high sodium intake: a longitudinal study in 1990–2019 in China
Authors: Shen Yongyao , Jiang Liying , Yu Jin , Chen Bo , Liu Aidong , Guo Yongjin 
Published: January 2025

ObjectiveElevated sodium consumption is associated with increased risk for chronic kidney disease (CKD) and data for this disease burden attributable to high sodium intake in China from 1990 to 2019 are scarce in China. Our study aims to estimate and present the national burden of CKD attributable to high sodium intake, as well as its profile.MethodsThe regional disease burden data from the China Center for Food Safety Risk Assessment (CFSA) from 1990 to 2019 were compiled based on the methodology of GBD 2019. CKD burden [deaths and disability-adjusted life years (DALYs)] was quantified according to population group (age, gender) and regions categories (province, SDI). The estimated annual percentage change (EAPC) in age-standardized mortality rate (ASMR) and age-standardized DALYs rate (ASDR) were calculated to describe long-term trends.ResultsTotally, the number of deaths of CKD attributable to high sodium intake reached 95,000, with DALYs amounting to 2.59 million person-years in 2019, while the trends of ASMR (EAPC: -0.31, 95%CI: −0.46, −0.17%) and ASDR (−0.33, 95%CI: −0.48, −0.18%) were down during the observation period. The age-specific numbers and rates of deaths, as well as DALYs increase with age are higher in males than in females. Significant disparities in CKD burden attributable to high sodium intake were observed across provinces and SDI regions. In both 1990 and 2019, the number of deaths and DALYs were higher in middle SDI regions, while low-middle SDI regions had highest ASMR and ASDR. The EAPC of ASDR was found to be significantly negatively correlated with the 1990 ASDR (ρ = −0.393, p = 0.024), and the EAPC of ASMR and ASDR were also significantly negatively correlated with the 2019 SDI (ASMR:ρ = −0.571, p &lt; 0.001; ASDR:ρ = −0.368, p = 0.035).ConclusionHigh sodium intake accounted for a sizeable burden of disease from 1990 to 2019 in China, also presents sexual and geographic variations. Despite a slight decreasing trend exists, the absolute number increased as much as twofold, particularly among males and seniors. Targeting to reduce sodium intake remains a priority, and progress requires systematic monitoring and evaluation, particularly in middle SDI regions that are experiencing rising trends and low-middle SDI regions being susceptible to approaches.
Gut microbiota, metabolites, and cytokines in relation to the risk of prostate cancer in the Asian population
Authors: Wang Zhengshi , Chen Haotian , Liu Yongqiang , Zou Libin , Zhang Zhijin , Yin Zhiqiang , Mao Shiyu , Guo Changcheng , Yang Bin , Wu Pengfei , Yao Xudong 
Published: January 2025

PurposeStudies have shown that gut microbiota is involved in the tumorigenesis and development of prostate cancer. We aimed to perform a comprehensive analysis of causal associations of gut microbiota, metabolites, and cytokines with prostate cancer in the Asian population.Patients and methodsGenome-wide association study (GWAS) summary datasets were collected from the public databases. There were 418 bacterial traits, 452 metabolites, 91 cytokines, 5408 cases of prostate cancer from East Asia, and 109,347 controls included. Mendelian randomization (MR) analyses were performed to investigate their causal relationships. Sensitivity analyses were conducted to test the reliability of MR results. Furthermore, the FinnGen database was used to assess the generalizability of our findings based on Asians.ResultsThere were a total of 17 bacterial traits, 28 metabolites (including 2 microbiota-associated metabolites), and 9 cytokines to be significantly associated with prostate cancer in Asians (P &lt; 0.05). Further MR analyses of these positive results indicated that G_Ruminococcaceae UCG014/TNFSF10 axis, G_Anaerofilum/TNFRSF14 axis, G_Erysipelotrichaceae UCG003/TNFSF10 axis, and P_Proteobacteria/cholesterol axis were key signaling pathways involved in the progression of prostate cancer. Notably, G_Ruminococcaceae UCG014/TNFSF10 axis and G_Anaerofilum/TNFRSF14 axis were found to act as protective factors, while the other two signaling axes played a crucial role in promoting the progression of prostate cancer. Sensitivity analyses further confirmed the reliability of our findings. Using the European population as outcome, we further assessed the generalizability of our conclusions and found limited applicability to Europeans.ConclusionsWe found that there were causal associations of gut microbiota, metabolites, and cytokines with prostate cancer in Asians. The causal effects of gut microbiota on prostate cancer were partially mediated by metabolites and cytokines. These findings might contribute to the development of new therapeutic strategies for prostate cancer.
Seeing beyond words: nanotechnology in hepatocellular carcinoma - a bibliometric study
Authors: Tuergan Talaiti , Abulaiti Aimitaji , Tulahong Alimu , Zhang Ruiqing , Yuan Zhongdian , Lin Yanze , Shao Yingmei , Aji Tuerganaili 
Published: January 2025

BackgroundNanotechnology has increasingly been applied in the diagnosis and treatment of hepatocellular carcinoma (HCC) over the past two decades. This study aims to explore the utilization of nanotechnology in HCC through a bibliometric analysis, identifying key themes, trends, and contributions in this field.MethodsThe study utilized VOSviewer and CiteSpace software to perform a bibliometric analysis, evaluating scholarly contributions related to nanotechnology in HCC. The analysis focused on co-occurrence network relationships, publications, citations, and contributions from various entities and authors.ResultsThe analysis revealed a total of 2,968 articles, with China and the USA being the most prominent contributors in terms of publications and citations. Notable contributions were made by the Chinese Academy of Sciences and authors Gao Jie and Li Yan. LLOVET JM emerged as the most co-cited author, indicating a leadership role in the field. The “International Journal of Nanomedicine” was identified as the leading publisher, while “Biomaterials” ranked highest in citations. The research mainly focused on drug delivery systems and apoptosis, highlighting significant advancements in utilizing nanotechnology for HCC treatment.ConclusionThis bibliometric study underscores the critical role of nanotechnology in advancing the diagnosis and treatment of hepatocellular carcinoma, with a particular emphasis on drug delivery and apoptosis. The findings highlight the contributions of key countries, institutions, and authors, reflecting the global effort and collaboration in this rapidly evolving field.
Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis
Authors: Xu Hongkun , Lu Tingting , Liu Yajie , Yang Jingqi , Ren Simeng , Han Baojin , Lai Honghao , Ge Long , Liu Jie 
Published: January 2025

ObjectiveThe prevalence of long COVID among cancer patients remains unknown. This study aimed to determine the prevalence of long COVID and explore potential risk factors among cancer patients.MethodsA systematic search was performed on PubMed, Web of Science, and Embase from database inception until 21 March 2024, to identify studies that reported long COVID in cancer patients. Two investigators independently screened the studies and extracted all information about long COVID in cancer patients for subsequent analysis. Methodological quality was assessed using the “Joannagen Briggs Institute (JBI) Critical Appraisal Checklist for Studies Reporting Prevalence Data”.ResultsA total of 13 studies involving 6,653 patients were included. The pooled prevalence of long COVID was 23.52% [95% confidence interval (CI), 12.14% to 40.64%] among cancer patients reported experiencing long COVID after acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The pooled prevalence of any long COVID in cancer patients was 20.51% (95% CI, 15.91% to 26.03%), 15.79% (95% CI, 11.39% to 21.47%), and 12.54% (95% CI, 6.38% to 23.18%) in 3, 6, and 12 months follow-up duration. Fatigue was the most common symptom, followed by respiratory symptoms, myalgia, and sleep disturbance. Patients with comorbidities had a significantly higher risk of experiencing long COVID [odds ratio (OR) = 1.72; 95% CI, 1.09 to 2.70; p = 0.019]. No statistically significant differences in sex, primary tumor, or tumor stage were detected.ConclusionNearly a quarter of cancer patients will experience long COVID after surviving from SARS-CoV-2 infection, and this would even last for 1 year or longer. Fatigue, respiratory symptoms, myalgia, and sleep disturbance need to be more addressed and managed to reduce symptom burden on cancer patients and improve quality of life. Patients with comorbidities are at a high risk of developing long COVID. Further randomized controlled trials with rigorous methodological designs and large sample sizes are needed for future validation.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023456665.
Magnetic beads as intravesical foreign bodies in children: our clinical experience
Authors: Zeng Yefeng , Huang Shaogang , Yang Zhilin , Gu Xianbin , Sun Xuerui , Chen Pengyu , Li Shoulin 
Published: January 2025

PurposeTo analyze the clinical data of five patients involving intravesical magnetic beads, summarizing diagnostic and therapeutic experiences.MethodsFrom January 2018 to November 2023, five pediatric patients were treated for intravesical magnetic beads at Shenzhen Children's Hospital. We retrospectively reviewed and analyzed the records of these patients, including demographic characteristics, clinical symptoms, imaging studies, and treatment methods.ResultsAll intravesical magnetic beads were retrieved from patients’ bladders. The patients ranged from 12 to 14 years, with a mean age of 13 years. None of them had a history of psychiatric disorders. Depending on the number of magnetic beads, their aggregation state, and the time since insertion, Three cases were successfully retrieved via cystoscopy, one via pneumovesicoscopy, and another via open surgery. No complications were observed during the postoperative follow-up.ConclusionMagnetic beads are a relatively rare type of intravesical foreign bodies and should be surgically removed as soon as possible. Cystoscopy is the first method for both diagnosis and treatment. When magnetic beads cannot be retrieved via cystoscopy, pneumovesicoscopy may be a viable option for the retrieval of foreign bodies. When endoscopic techniques are unsuitable or have failed, open surgery is a necessary option.
The chiisanoside derivatives present in the leaves of Acanthopanax sessiliflorus activate autophagy through the LRP6/GSK3β axis and thereafter inhibit oxidative stress, thereby counteracting cisplatin-induced ototoxicity
Authors: Zhang Wenxin , Teng Hongbo , Zhao Tianyi , Eglitis Roberts I. , Wang Xv , Yu Zhengxuan , Qu Shurong , Wang Haijing , Zhao Yaru , Fan Bowen , Liu Shuangli , Zhao Yan 
Published: January 2025

IntroductionCisplatin is extensively employed in the treatment of multiple solid malignant tumors. Nevertheless, side effects such as cisplatin-induced ototoxicity (CIO) pose obstacles to tumor therapy.The important natural product chiisanoside from Acanthopanax sessiliflorus has abundant activity against CIO.MethodsIn this study, 26 chiisanoside derivatives were screened, and compound 19 demonstrated significant protective activity against CIO damage. A cisplatin—induced HEI—OC1 cell injury model and a mouse ototoxicity model were established. The regulatory effects were revealed through transcriptome sequencing, and the protein expression levels were analyzed by molecular docking, ELISA, Western blotting, and immunofluorescence.ResultsIt was found that compound 19 inhibited cell apoptosis, alleviated abnormal hearing and spiral ganglion damage. Transcriptome sequencing revealed its regulatory effects. Compound 19 treatment increased autophagy levels, thereby alleviating mitochondrial dysfunction and reducing the accumulation of reactive oxygen species (ROS).In-depth studies have found that the autophagy inhibitor 3-methyladenine (3-MA) weakens the regulatory effect of compound 19 on autophagy and inhibits the clearance of damaged cells, resulting in oxidative stress damage, apoptosis and necrosis. By knocking down LRP6, it was found that the protective effect of compound 19 was eliminated, the autophagy level was significantly reduced, oxidative stress and ROS production were induced, and apoptosis after cisplatin exposure was promoted. Finally, the inhibitor LiCl was used to suppress the expression of GSK3β. It was found that inhibiting GSK3β could protect cells from cisplatin-induced damage by activating autophagy.DiscussionThese findings suggest that compound 19 is capable of preventing ototoxicity by activating autophagy via the LRP6/GSK3β axis and consequently inhibiting oxidative stress, offering a new approach for treating CIO and sensorineural hearing loss.
Protective effect of resveratrol on retinal damage in glaucoma: a systematic review and meta-analysis of preclinical studies
Authors: Zhang Feng , Li Tao , Wan Junli , Wang Lu , Guo Wenmei , Hu Yue , Wang Hao , Bian Wei 
Published: January 2025

IntroductionResveratrol, a polyphenolic compound commonly found in natural plants and fruits, exhibits potential in preventing optic nerve damage in glaucoma, as indicated by several animal studies. However, there is presently a dearth of relevant evidence available for comprehensive summarization.MethodsIn this study, we conducted an extensive search across 7 electronic databases, encompassing all pertinent animal studies for a systematic review and meta-analysis. Methodological quality was evaluated using SYRCLE’s bias risk tool, with statistical analysis performed using Stata 17.0. The primary outcome measures included the survival of retinal ganglion cells and retinal thickness.ResultsThe comprehensive analysis of the 30 included studies revealed that resveratrol can enhance the expression of Sirtuin 1(SIRT1) protein in retinal tissue (SMD: 3.00, 95% CI: 2.46, 3.53, P = 0.095), boost the survival rate of retinal ganglion cells (SMD: 4.33, 95% CI: 3.28, 5.38, P &lt; 0.05), decelerate the thinning of retinal thickness (SMD: 4.26, 95% CI: 2.77, 5.75, P &lt; 0.05), and enhance visual function. Its potential mechanism of action may involve the suppression of pro-inflammatory cytokine levels and cell apoptosis.DiscussionResveratrol emerges as a promising agent for mitigating glaucoma-related retinal damage. However, given that the animal research models utilized in the study may not fully reflect the intricate scenarios of multiple coexisting diseases in clinical settings, and the administration methods in animal models may differ from those in clinical practice, future studies should aim to provide higher levels of evidence to facilitate the clinical translation of these findings.Systematic Review Registration:identifier [CRD42024535673].
The efficacy and safety of first-line monotherapies in primary therapy of invasive aspergillosis: a systematic review
Authors: Chen Yan , Zhao Jiaojiao , Wang Yifei , Ge Long , Kwong Joey Sum-wing , Lan Junjie , Zhang Rui , Zhao Huaye , Hu Linfang , Wang Jiaxue , Sun Shuimei , Tan Songsong , Lin Xiaoqing , He Rui , Zheng Wenyi , Li Xiaosi , Zhang Jiaxing 
Published: January 2025

ObjectiveSeveral antifungals are available for the treatment of patients with invasive aspergillosis (IA). This study aims to evaluate the relative efficacy and safety of the first-line monotherapies in primary therapy of IA through network meta-analysis (NMA).MethodsWe systematically searched PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, VIP database, Wanfang database, and China Biology Medicine for randomized controlled trials (RCTs) up to July 2023 that evaluated the efficacy and safety of monotherapies. We performed NMA with a frequentist random effects model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Primary outcomes were the all-cause mortality at week 12, and secondary outcomes included overall response rate, and incidence of adverse events (AEs) and severe adverse events (SAEs).ResultsA total of three RCTs involving 1,368 participants (four antifungals) were included. The NMA showed that compared to amphotericin B deoxycholate (D-AmB), the triazoles (posaconazole (POS), isavuconazole (ISA) and voriconazole (VCZ)) can improve the overall response rate in primary therapy of IA, but only VCZ and ISA can reduce the all-cause mortality at week 12 for patients with proven and probable IA (VCZ vs D-AmB: RR = 0.66, 95%CI = 0.47–0.93, moderate certainty; ISA vs D-AmB: RR = 0.52, 95%CI = 0 .31–0.86, low certainty). ISA (SUCRA = 93.50%; mean rank, 1.20) seemed to be the most effective therapy in the above population. As to proven, probable, and possible IA patients, the triazoles were superior to D-AmB in terms of reducing all-cause mortality. Furthermore, the risk of AEs and SAEs was comparable for the three triazoles, but the risk of SAEs was significantly higher for D-AmB than others.ConclusionThe efficacy and safety of triazoles are more favorable than D-AmB in the primary therapy of IA, with ISA being the optimal choice.Systematic Review RegistrationPROSPERO CRD42023407632.